Q&A Part 2: Reviewing the Significance of Lebrikizumab for Patients With Skin of Color, With Anabela Cardoso, MD
Summary by dermatologytimes.com
1 Articles
1 Articles
All
Left
Center
Right
Q&A Part 2: Reviewing the Significance of Lebrikizumab for Patients With Skin of Color, With Anabela Cardoso, MD
Anabela Cardoso, MD, reflects on specific data from the phase 3b ADmirable trial evaluating the safety and efficacy of lebrikizumab in patients with moderate to severe AD and pigmented skin.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium